UBX vs. SNSE, VAXX, ENLV, LPCN, EYEN, ITRM, DRRX, QLI, GDTC, and ONCT
Should you be buying Unity Biotechnology stock or one of its competitors? The main competitors of Unity Biotechnology include Sensei Biotherapeutics (SNSE), Vaxxinity (VAXX), Enlivex Therapeutics (ENLV), Lipocine (LPCN), Eyenovia (EYEN), Iterum Therapeutics (ITRM), DURECT (DRRX), Qilian International Holding Group (QLI), CytoMed Therapeutics (GDTC), and Oncternal Therapeutics (ONCT). These companies are all part of the "pharmaceutical preparations" industry.
Unity Biotechnology (NASDAQ:UBX) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, community ranking, profitability, media sentiment, analyst recommendations, risk and institutional ownership.
Sensei Biotherapeutics has lower revenue, but higher earnings than Unity Biotechnology. Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Unity Biotechnology, indicating that it is currently the more affordable of the two stocks.
In the previous week, Sensei Biotherapeutics had 1 more articles in the media than Unity Biotechnology. MarketBeat recorded 3 mentions for Sensei Biotherapeutics and 2 mentions for Unity Biotechnology. Sensei Biotherapeutics' average media sentiment score of 0.33 beat Unity Biotechnology's score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.
Unity Biotechnology received 150 more outperform votes than Sensei Biotherapeutics when rated by MarketBeat users. However, 75.86% of users gave Sensei Biotherapeutics an outperform vote while only 66.15% of users gave Unity Biotechnology an outperform vote.
Sensei Biotherapeutics' return on equity of -44.01% beat Unity Biotechnology's return on equity.
29.5% of Unity Biotechnology shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 4.9% of Unity Biotechnology shares are held by company insiders. Comparatively, 25.5% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Unity Biotechnology currently has a consensus price target of $6.00, indicating a potential upside of 300.00%. Sensei Biotherapeutics has a consensus price target of $4.00, indicating a potential upside of 292.16%. Given Unity Biotechnology's higher probable upside, research analysts clearly believe Unity Biotechnology is more favorable than Sensei Biotherapeutics.
Unity Biotechnology has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500.
Summary
Sensei Biotherapeutics beats Unity Biotechnology on 8 of the 15 factors compared between the two stocks.
Get Unity Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Unity Biotechnology Competitors List
Related Companies and Tools
